TABLE 4.
Factors associated with DAA failure
| DAA failure | Crude OR | Adjusted Model 1 | Adjusted Model 2 | ||||
|---|---|---|---|---|---|---|---|
| n/N (%) | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Age, y | |||||||
| 20‐39 | 9/596 (1.5) | 1 | |||||
| 40‐59 | 76/4442 (1.7) | 1.14 (0.57‐2.28) | .72 | ||||
| 60‐79 | 131/7883 (1.7) | 1.10 (0.56‐2.18) | .78 | ||||
| ≥80 | 20/1027 (2.0) | 1.30 (0.59‐2.86) | .52 | ||||
| Gender | |||||||
| Male | 115/6149 (1.9) | 1.21 (0.94‐1.57) | .15 | ||||
| Female | 121/7802 (1.5) | 1 | |||||
| Prior treatment | 1 | 1 | |||||
| No | 172/10 978 (1.6) | 1 | |||||
| Yes | 64/2973 (2.2) | 1.38 (1.03‐1.85) | .03 | 1.25 (0.89‐1.72) | .21 | 1.42 (1.00‐2.03) | .052 |
| DAA regiments | |||||||
| DCV/ASV | 24/556 (4.2) | 4.67 (1.77‐12.3) | .002 | 3.29 (1.94‐5.58) | <.001 | 5.99 (1.96‐18.38) | .002 |
| SOF + RBV | 61/1670 (3.7) | 3.93 (1.57‐9.83) | .004 | 2.51 (1.67‐3.77) | <.001 | 3.78 (1.50‐9.56) | .005 |
| Others | 151/11 646 (1.3) | 1 | – | – | |||
| SOF + LDV | 61/4101 (1.5) | 1.56 (0.63‐3.91) | .34 | – | 2.05 (0.78‐5.36) | .15 | |
| EBR/GZR | 29/2099 (1.4) | 1.45 (0.56‐3.77) | .44 | – | 2.96 (0.99‐8.80) | .052 | |
| PrOD | 31/2524 (1.2) | 1.29 (0.50‐3.33) | .60 | – | 1.33 (0.44‐4.02) | .62 | |
| SOF/VEL | 5/410 (1.2) | 1.28 (0.37‐4.45) | .70 | – | 1.40 (0.39‐5.00) | .61 | |
| GLE/PIB | 20/1989 (1.1) | 1.05 (0.39‐2.82) | .92 | – | 1.18 (0.42‐3.29) | .75 | |
| SOF/DCV | 5/523 (1.0) | 1 | – | 1 | |||
| HCV RNA, IU/mL | |||||||
| <6,000,000 | 176/11 731(1.5) | 1 | 1 | 1 | |||
| > 6,000,000 | 60/2179 (2.8) | 1.87 (1.39‐2.51) | <.0001 | 2.16 (1.57‐2.97) | <.001 | 2.14 (1.55‐2.95) | <.001 |
| HCV genotype | |||||||
| 1 | 114/8192 (1.4) | 1 | 1 | 1 | |||
| 2 | 107/5031 (2.1) | 1.54 (1.18‐2.01) | .002 | 1.55 (1.05‐2.29) | .03 | 2.01 (1.21‐3.35) | .007 |
| 3 | 5/101 (5.0) | 3.69 (1.47‐9.24) | .005 | 5.78 (2.25‐14.9) | .0003 | 9.50 (3.22‐27.99) | <.001 |
| others | 10/627 (1.6) | 1.15 (0.60‐2.20) | .68 | 1.66 (0.84‐3.27) | .14 | 1.79 (0.86‐3.72) | .12 |
| DAA adherence | |||||||
| >80% | 215/13 903 (1.5) | 1 | 1 | 1 | |||
| 60%‐80% | 1/14 (7.1) | 4.90 (0.64‐37.06) | .12 | 6.03 (0.74‐49.1) | .09 | 6.49 (0.79‐53.62) | .08 |
| <60% | 20/34 (58.8) | 90.95 (45.34‐182.45) | <.0001 | 117.1 (52.4‐261.3) | <.001 | 135.74 (59.16‐311.44) | .0009 |
| HBV dual infection | |||||||
| No | 220/12 883 (1.7) | 1.14 (0.69‐1.91) | .61 | ||||
| Yes | 16/1068 (1.5) | 1 | |||||
| HIV coinfection | |||||||
| No | 209/12 397 (1.7) | 1 | |||||
| Yes | 4/154 (2.6) | 1.56 (0.57‐4.24) | .39 | ||||
| CKD | |||||||
| No | 196/11 653 (1.7) | 1 | |||||
| Yes | 40/2292 (1.7) | 1.04 (0.74‐1.46) | .83 | ||||
| PWID | |||||||
| Yes | 3/243 (1.2) | 1 | |||||
| No | 233/13 708 (1.7) | 1.38 (0.44‐4.35) | .58 | ||||
| LC | |||||||
| No LC | 117/8581 (1.4) | 1 | 1 | 1 | |||
| CLC | 94/4421 (2.1) | 1.57 (1.20‐2.07) | .0012 | 1.20 (0.89‐1.61) | .24 | 1.26 (0.93‐1.70) | .14 |
| DLC | 10/242 (4.1) | 3.12 (1.61‐6.03) | .0007 | 2.50 (1.20‐5.22) | .02 | 2.53 (1.19‐5.39) | .02 |
| HCC | |||||||
| No | 185/12 478 (1.5) | 1 | 1 | 1 | |||
| Yes, inactive | 28/1145 (2.4) | 1.67 (1.11‐2.49) | .01 | 1.44 (0.90‐2.30) | .13 | 1.47 (0.92‐2.34) | .11 |
| Yes, active | 23/328 (7.0) | 5.01 (3.20‐7.84) | <.0001 | 4.29 (2.57‐7.16) | <.001 | 4.37 (2.62‐7.31) | <.001 |
Abbreviations: ASV, asunaprevir; CKD, chronic kidney disease; CLC, compensated liver cirrhosis; DAA, direct‐acting antiviral; DCV, daclatasvir; DLC, decompensated liver cirrhosis; EBR, elbasvir; GLE, glecaprevir; GZR, grazoprevir; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; LC, liver cirrhosis; LDV, ledipasvir; OR, odds ratio; PIB, pibrentasvir; PrOD, paritaprevir/ritonavir/ombitasvir/dasabuvir; PWID, persons who inject drugs; SOF, sofosbuvir; VEL, velpatasvir.